So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of ...

Regular meetings with company management allow the team to ... for roughly 10% of the strategy’s assets. The team remains bullish on Eli Lilly's leadership in the weight-loss market and believes ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...